Pharmaceutical-Grade Production
Injectable-grade materials and cGMP whole-process management on a 2,000 m² industrialized platform.
VIEW MORE →Injectable-grade materials and cGMP whole-process management on a 2,000 m² industrialized platform.
VIEW MORE →Our patented tangential ultra-filtration delivers high-purity exosomes at stable, scalable volume.
VIEW MORE →Tailored exosome research and production to your application — from raw material to finished product.
VIEW MORE →5,000+ users and partners across Southeast Asia, Africa and Europe.
VIEW MORE →MYS-Exo focuses on exosome R&D, customization and regenerative medicine. We supply exosome products for facial care and body health care and deliver one-stop services including R&D, production, sales and after-sales.
We own multiple professional exosome technology and large-scale production platforms. We cooperate with more than 5,000 distributors and beauty institutions worldwide, and have completed over 80,000 sample tests. Our core technology has been published in top academic journals.
Our core exosome raw material holds US FDA DMF and INCI certifications. We also launched research projects to set industry quality standards. We strive to provide professional solutions for medical aesthetics, anti-aging and regenerative medicine.
Company Founded
Excellent Scientists
Collaborating with over 5000 medical aesthetic institutions and Users
Invention Research Paper
Technology Patents
OEM & Production Base Laboratory
MYS-Exo is founded, dedicated to exosome regenerative medicine.
Dedicated to exosome-based facial medical aesthetics and body-health medicine, as well as custom exosome product development.
Recognised as a National High-Tech Enterprise and a National SME; launched the life-science product series and exosome raw-material products.
Major business expansion and financing to scale production capacity.
Co-founded the “Nobel Studio” together with a Nobel Prize laureate in exosome science.
Postdoctoral fellow at the University of Washington (under Prof. Hakomori, member of the U.S. National Academy of Sciences). 20 years in oncology, glycobiology and exosome research; 60+ SCI papers in PNAS, JEV, Leukemia; 10 patents filed, 5 granted.
Postdoctoral fellow at the University of Washington; Shaanxi distinguished expert. 20 years in oncology, stem-cell and exosome research; 40+ papers in Blood, JEV, Leukemia and Haematologica.
MYS-Exo has partnered with Nobel laureates in exosomes to create the “Nobel Prize Studio.” This studio not only provides the company with strong scientific research support but also serves as a source of technology to help the company maintain its leading position in basic research and industrial applications of exosomes, providing a solid guarantee for the company’s innovation and driving continuous breakthroughs in exosome technology.
Our factory laboratory runs the entire workflow to GMP pharmaceutical standards.
01All raw, auxiliary and consumable materials are injectable grade, managed to cGMP pharmaceutical standards — fully traceable.
02Umbilical-cord MSCs pass 26-item QC: endotoxin, virus, phenotype, anti-inflammatory and regenerative factor secretion.
033D culture yields 3–5× more exosomes than 2D, with daily monitoring of viability, metabolism and secretion.
04Patented stable, scalable tangential ultra-filtration for high-purity, large-scale exosome extraction.
05Upgraded patented preservation formula keeps lyophilized exosomes optimally active at 2–8°C.
06Patented lyophilization and a fully automated aseptic filling line for efficient, sterile large-scale production.
07A 7-dimension quality system — identity, content, purity, bioactivity, impurity, pharmacopoeia and omics — with 30+ tests per batch.
08Every batch is activity-tested; a single failing indicator vetoes release, guaranteeing safety and efficacy.
National High-Tech Enterprise · ISO 9001 certified · award-winning exosome R&D, protected by 20 patents.
Partner with us for clinic supply, distribution and training across SEA, Africa & Europe.